1-Phenyl-2-Pyridinyl Alkyl Alcohol PDE4 Inhibitors for Selective Anti-Inflammatory Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for respiratory diseases like asthma and COPD have undesirable side effects due to their action on central nervous system and gastric cells, and existing second-generation inhibitors like roflumilast require dosing adjustments for an acceptable side effect profile, indicating a need for compounds with higher affinity for the low affinity rolipram binding site (LPDE4) to reduce systemic exposure and side effects.
Innovation Solution
Development of derivatives of 1-phenyl-2-pyridinyl alkyl alcohols with specific structural features that act as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, targeting LPDE4 to minimize side effects and optimize pharmacokinetic characteristics for inhalation treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation PDE4 inhibitors (rolipram, piclamilast) are used, then strong anti-inflammatory effects are achieved, but severe side effects occur (nausea, emesis, gastric acid secretion)
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (1-phenyl-2-pyridinyl alkyl alcohol scaffold with particular substituents) that confer selective affinity for LPDE4 over HPDE4. This selectivity creates a localized effect on inflammatory cells while minimizing interaction with central nervous system and gastric PDE4 isoforms, thereby reducing systemic side effects while maintaining anti-inflammatory efficacy
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure parameters of PDE4 inhibitors to achieve differential binding affinity. By modifying substituents on the core scaffold (such as introducing specific R1, R2, R3 groups as defined in the patent), the compounds achieve higher selectivity for LPDE4, changing the binding parameter to favor inflammatory cell targets over other tissues
2Object-affected harmful factors
If second-generation PDE4 inhibitor (roflumilast) is used, then side effects are reduced, but dosing adjustments are required to achieve acceptable side effect profile
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure to achieve even higher LPDE4 selectivity than roflumilast. The specific substituent patterns (such as R1 being hydrogen, lower alkyl, or lower haloalkyl; R2 being lower alkyl or lower haloalkyl) fine-tune the binding parameters to maximize selectivity, allowing for more flexible dosing while maintaining an acceptable side effect profile
3Power
If PDE4 inhibitors with high affinity for HPDE4 are used, then strong inhibition is achieved, but side effects increase due to action on central nervous system and gastric cells
Solution Approach 1:
The patent applies local quality by creating compounds with selective affinity for LPDE4 through specific structural features. The 1-phenyl-2-pyridinyl alkyl alcohol scaffold with particular substituents creates a localized interaction pattern that matches LPDE4 binding pocket characteristics, producing strong inhibition in inflammatory cells while sparing HPDE4 in the central nervous system and gastric cells
Solution Approach 2:
The patent employs an intermediary approach by using the LPDE4 binding site as a selective mediator. The compounds act as intermediaries that preferentially bind to and inhibit LPDE4, creating a selective pathway for anti-inflammatory action while avoiding the harmful intermediary interactions with HPDE4 in sensitive tissues
Data Source
AI summary
The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.